A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancerXiaodong Liu, Zhongsheng Tong, Yongsheng Jia et al.|Therapeutic Advances in Medical Oncology|2024Cited by 2